{"id":"W4381548535","doi":"10.1136/jitc-2022-006589","title":"G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Astellas Pharma; Daiichi-Sankyo; Genentech; Coherus Biosciences; Servier; Moderna; Revolution Medicines; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Foghorn Therapeutics; Mallinckrodt Pharmaceuticals; Boston Scientific Corporation; Pharmavite; Ludwig Center at Harvard; GlaxoSmithKline; Pfizer; Break Through Cancer; National Institute of Allergy and Infectious Diseases; Celgene","keywords":"FOLFIRINOX; Pegfilgrastim; Medicine; Filgrastim; Gemcitabine; Immunology; Pancreatic cancer; Neutropenia; Granulocyte colony-stimulating factor; Chemotherapy; Cancer research; Internal medicine; Cancer; Irinotecan","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000446061,0.000679061,0.0004507423,0.0005369487,0.000225185,0.0004571324,0.0003131972,0.0007433646,0.001989038],"category_scores_gemma":[0.0001686492,0.0001928006,0.0004070231,0.0001326621,0.0004436625,0.0002790481,0.0001759322,0.001103587,0.0005328544],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000351724,"about_ca_system_score_gemma":0.000262796,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003758665,"about_ca_topic_score_gemma":0.0004015285,"domain_scores_codex":[0.9997672,0.00006223623,0.00002029404,0.00006149818,0.00004010811,0.00004863015],"domain_scores_gemma":[0.999863,0.00002025549,0.00004107015,0.0000286448,0.00000853051,0.00003832257],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003655106,0.001236356,0.0009996255,0.0001473745,0.00005285391,0.0003827677,0.00008460147,0.0004166002,0.9773316,0.0005687053,0.00136181,0.01376264],"study_design_scores_gemma":[0.00220517,0.02465845,0.01602097,0.0001595897,0.0002374487,0.007296353,0.0001552626,0.005334548,0.909234,0.0006138245,0.03404159,0.00004271332],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9827292,0.005935654,0.004738884,0.0005461978,0.0001205204,0.0002991222,0.001380549,0.0004811113,0.003768767],"genre_scores_gemma":[0.9900096,0.00209865,0.00223662,0.0004267606,0.00003967842,0.0003368435,0.001251681,0.00005022912,0.003550007],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001989038,"threshold_uncertainty_score":0.006653965,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02184843116684437,"score_gpt":0.323270584917015,"score_spread":0.3014221537501707,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}